The study, published in the journal Neurology, Italian scientists on the basis of MRI indices of disease activity compared the efficacy of treatment of exacerbations of multiple sclerosis with high-dose methylprednisolone, intravenous and oral

The study included 40 patients with relapsing-remitting multiple sclerosis who developed within 2 weeks of aggravation and at least one fireplace, accumulating a contrast agent for MRI. All patients were randomized into 2 groups, the first of which received methylprednisolone 1000 mg intravenously, and the second - in the mouth for 5 consecutive days. Before treatment, after 1 and 4 weeks was assessed the severity of neurological symptoms on a scale expanded disability (EDSS), as well as the presence of MRI lesions, accumulate contrast agent. The aim of the study was to evaluate the short-term efficacy, tolerability and safety of two routes of administration of the drug. In both treatment groups indicated a significant reduction in lesions accumulate contrast, the improvement of EDSS, good tolerability and minimal side effects. The authors conclude comparable to the effectiveness of intravenous and oral administration of high doses of methylprednisolone at 1 and 4 weeks. However, to develop specific recommendations and implementation into clinical practice requires a more representative and long-term studies

Source